US equities |
SPCX $167.02 ▲+5.07% NVDA $236.91 ▲+1.27% MU $1,063.58 ▼-1.05% TSLA $377.24 ▲+1.79% MSFT $526.27 ▲+1.69% SNDK $1,709.12 ▼-0.63% INTC $117.22 ▼-1.77% META $743.91 ▲+2.17%
FinancialContent

Articles published by Natera, Inc.

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera Reports Second Quarter 2026 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera to Report its Second Quarter Results on August 6, 2026
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
From Natera, Inc.
Via Business Wire
Tickers ELDN NTRA
News headline image
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire
Tickers CYDY NTRA
News headline image
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera Reports First Quarter 2026 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera to Report its First Quarter Results on May 7, 2026
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
From Natera, Inc.
Via Business Wire
Tickers NTRA
< Previous 1 2 3 4 5 6 7 Next >